Comparison of monotherapy versus add-on treatment differences for LMTM 4 mg twice a day and 100 mg twice a day. Data expressed as mean with 95% CI.
Co-primary outcomes examining LMTM 100 mg twice a day as monotherapy compared with the control arm as randomized (Comparison A), and LMTM 4 mg twice a day as monotherapy compared with 4 mg twice a day as add-on to existing Alzheimer's disease treatments (Comparison B) after removal of patients taking a cholinesterase inhibitor in combination with memantine from the analysis. Data expressed as mean with 95% CI.
Comparison

Wilcock et al. Supplementary material -page 4
Supplementary Table 2b
Co-primary outcomes examining LMTM 100 mg twice a day as monotherapy compared with 100 mg twice a day as add-on to existing Alzheimer's disease treatments (Comparison C) after removal of patients taking a cholinesterase inhibitor in combination with memantine from the analysis. Comparison of volumetric MRI outcomes according to CDR severity at baseline. Differences are shown with respect to the control change from baseline at 78 weeks as specified for comparisons A and B. Two parallel implementations of sequential tests were prespecified to examine LMTM 100 mg twice a day as monotherapy compared with the control arm as randomized (comparison A), and LMTM 4 mg twice a day as monotherapy compared with 4 mg twice a day as add-on to existing Alzheimer's disease treatments (comparison B). CI 2905, 3111 -135, -108 -38, 40 -139, -111 11, 82 Volumetric MRI outcomes comparing LMTM 100 mg twice a day as monotherapy with 100 mg twice a day as add-on to existing AD treatments (Comparison C). 
